Analyst Review Alert: SLM Corporation (NASDAQ:SLM)

Analysts are weighing in on how SLM Corp (NASDAQ:SLM), might perform in the near term. Wall Street analysts have a  assessment of the stock, with a mean rating of 2.0. The stock is rated as buy by 5 analysts, with 2 outperform and 2 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 8.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.11 a share, which would compare with $0.20 in the same quarter last year. They have a high estimate of $0.12 and a low estimate of $0.10. Revenue for the period is expected to total nearly $216.48M from $168.26M the year-ago period.

For the full year, 8.00 Wall Street analysts forecast this company would deliver earnings of 0.51 per share, with a high estimate of $0.52 and a low estimate of $0.50. It had reported earnings per share of $0.59 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $901.41M versus 702.50M in the preceding year.

The analysts project the company to maintain annual growth of around 10.45% percent over the next five years as compared to an average growth rate of 10.60% percent expected for its competitors in the same industry.

Among the 8 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for SLM is $9.38 but some analysts are projecting the price to go as high as $11.00. If the optimistic analysts are correct, that represents a 73 percent upside potential from the recent closing price of $6.37. Some sell-side analysts, particularly the bearish ones, have called for $8.00 price targets on shares of SLM Corp (NASDAQ:SLM).

In the last reported results, the company reported earnings of $0.20 per share, while analysts were calling for share earnings of $0.20. It was an earnings surprise of 0.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

SLM Corporation, together with its subsidiaries, operates as a saving, planning, and paying for education company in the United States. It offers private education loans to students and their families. The company also provides banking products, such as certificates of deposits, money market deposit accounts, and high yield savings accounts; and a consumer savings network that offers financial rewards on everyday purchases to help families save for college. SLM Corporation is headquartered in Newark, Delaware.

Analyst Review Alert: SM Energy Co (SM)

Analysts are weighing in on how SM Energy Co (NYSE:SM), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.7. The stock is rated as buy by 5 analysts, with 2 outperform and 19 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 21.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.77 a share, which would compare with $0.49 in the same quarter last year. They have a high estimate of $-0.56 and a low estimate of $-0.99. Revenue for the period is expected to total nearly $327.08M from $516.15M the year-ago period.

For the full year, 21.00 Wall Street analysts forecast this company would deliver earnings of -3.24 per share, with a high estimate of $-1.69 and a low estimate of $-4.06. It had reported earnings per share of $-0.53 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $1.24B versus 1.56B in the preceding year.

The analysts project the company to maintain annual growth of around 25.83% percent over the next five years as compared to an average growth rate of 8.52% percent expected for its competitors in the same industry.

Among the 20 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for SM is $31.77 but some analysts are projecting the price to go as high as $58.00. If the optimistic analysts are correct, that represents a 92 percent upside potential from the recent closing price of $30.17. Some sell-side analysts, particularly the bearish ones, have called for $15.00 price targets on shares of SM Energy Co (NYSE:SM).

In the last reported results, the company reported earnings of $0.49 per share, while analysts were calling for share earnings of $-0.01. It was an earnings surprise of 5,000.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

SM Energy Company, an independent energy company, engages in the acquisition, exploration, development, and production of crude oil and condensate, natural gas, and natural gas liquids in onshore North America. It primarily has operations in the South Texas and Gulf Coast region, which focuses primarily on Eagle Ford shale program; Rocky Mountain region comprising the Bakken and Three Forks formations in the North Dakota; and Permian region covering western Texas and southeastern New Mexico. As of December 31, 2015, the company had 471.3 million barrels of oil equivalent of estimated proved reserves; and working interests in 872 net productive oil wells and 653 net productive gas wells. The company was formerly known as St. Mary Land & Exploration Company and changed its name to SM Energy Company in May 2010. SM Energy Company was founded in 1908 and is headquartered in Denver, Colorado.

Analyst Review Alert: TerraForm Power Inc (NASDAQ:TERP)

Analysts are weighing in on how TerraForm Power Inc (NASDAQ:TERP) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.7. The stock is rated as buy by 1 analysts, with 1 outperform and 4 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 8.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.33 a share, which would compare with $0.00 in the same quarter last year. They have a high estimate of $-0.01 and a low estimate of $-1.14. Revenue for the period is expected to total nearly $121.30M from $42.57M the year-ago period.

For the full year, 3.00 Wall Street analysts forecast this company would deliver earnings of -0.61 per share, with a high estimate of $-0.34 and a low estimate of $-0.93. It had reported earnings per share of $-0.03 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $485.19M versus 125.86M in the preceding year.

The analysts project the company to maintain annual growth of around 10.00% percent over the next five years as compared to an average growth rate of 6.59% percent expected for its competitors in the same industry.

Among the 7 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for TERP is $12.57 but some analysts are projecting the price to go as high as $20.00. If the optimistic analysts are correct, that represents a 119 percent upside potential from the recent closing price of $9.13. Some sell-side analysts, particularly the bearish ones, have called for $6.00 price targets on shares of TerraForm Power Inc (NASDAQ:TERP) .

In the last reported results, the company reported earnings of $0.00 per share, while analysts were calling for share earnings of $0.02. It was an earnings surprise of -100.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

TerraForm Power, Inc. owns and operates solar and wind generation assets serving utility, commercial, and residential customers. As of February 20, 2015, its portfolio consisted of solar and wind projects located in the United States, Canada, the United Kingdom, and Chile with an aggregate nameplate capacity of 1,507.3 megawatt. The company was formerly known as SunEdison Yieldco, Inc. and changed its name to TerraForm Power, Inc. in May 2014. The company was founded in 2014 and is based in Bethesda, Maryland. TerraForm Power, Inc. is a subsidiary of SunEdison Holdings Corp.

Analyst Review Alert: Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)

Analysts are weighing in on how Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.4. The stock is rated as buy by 1 analysts, with 1 outperform and 3 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 4.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.11 a share, which would compare with $-0.12 in the same quarter last year. They have a high estimate of $-0.08 and a low estimate of $-0.14.

For the full year, 5.00 Wall Street analysts forecast this company would deliver earnings of -0.33 per share, with a high estimate of $-0.15 and a low estimate of $-0.49. It had reported earnings per share of $0.54 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $6.00M versus 76.92M in the preceding year.

Among the 2 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for THLD is $7.00 but some analysts are projecting the price to go as high as $12.00. If the optimistic analysts are correct, that represents a 2827 percent upside potential from the recent closing price of $0.41. Some sell-side analysts, particularly the bearish ones, have called for $2.00 price targets on shares of Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) .

In the last reported results, the company reported earnings of $-0.12 per share, while analysts were calling for share earnings of $-0.14. It was an earnings surprise of 14.30%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Threshold Pharmaceuticals, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma; and Phase I/II clinical trials for multiple myeloma. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I clinical trials for advanced solid tumors; and Phase I/II clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing Tarloxotinib, an investigational hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with advanced non-squamous non-small cell lung cancer, as well as patients with squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license and co-development agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on Tarloxotinib; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

Analyst Review Alert: United Parcel Service, Inc. (NYSE:UPS)

Analysts are weighing in on how United Parcel Service, Inc. (NYSE:UPS), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.4. The stock is rated as buy by 2 analysts, with 8 outperform and 16 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 23.00 analysts offering adjusted EPS forecast have a consensus estimate of $1.43 a share, which would compare with $1.35 in the same quarter last year. They have a high estimate of $1.48 and a low estimate of $1.40. Revenue for the period is expected to total nearly $14.63B from $14.10B the year-ago period.

For the full year, 25.00 Wall Street analysts forecast this company would deliver earnings of 5.81 per share, with a high estimate of $5.95 and a low estimate of $5.75. It had reported earnings per share of $5.43 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $60.92B versus 58.36B in the preceding year.

The analysts project the company to maintain annual growth of around 9.72% percent over the next five years as compared to an average growth rate of 17.88% percent expected for its competitors in the same industry.

Among the 20 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for UPS is $109.90 but some analysts are projecting the price to go as high as $126.00. If the optimistic analysts are correct, that represents a 18 percent upside potential from the recent closing price of $107.22. Some sell-side analysts, particularly the bearish ones, have called for $90.00 price targets on shares of United Parcel Service, Inc. (NYSE:UPS).

In the last reported results, the company reported earnings of $1.35 per share, while analysts were calling for share earnings of $1.27. It was an earnings surprise of 6.30%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

United Parcel Service, Inc., a package delivery company, provides transportation, logistics, and financial services in the United States and internationally. It operates in three segments: U.S. Domestic Package, International Package, and Supply Chain & Freight. The U.S. Domestic Package segment offers time-definite delivery of letters, documents, small packages, and palletized freight through air and ground services in the United States. The International Package segment provides guaranteed day and time-definite international shipping services in Europe, the Asia Pacific, Canada and Latin America, the Indian sub-continent, the Middle East, and Africa. It offers guaranteed time-definite express options, including Express Plus, Express, and Express Saver. The Supply Chain & Freight segment offers international air and ocean freight forwarding, customs brokerage, truckload freight brokerage, distribution and post-sales services, and mail and consulting services in approximately 220 countries and territories; and less-than-truckload and truckload services to customers in North America. The company also offers shipping, visibility, and billing technologies; and insurance, financing, and payment services. It operates a fleet of approximately 110,000 package cars, vans, tractors, and motorcycles; and owns 33,000 containers used to transport cargo in its aircraft. United Parcel Service, Inc. was founded in 1907 and is headquartered in Atlanta, Georgia.

Analyst Review Alert: Zions Bancorp (NASDAQ:ZION)

Analysts are weighing in on how Zions Bancorp (NASDAQ:ZION) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.3. The stock is rated as buy by 11 analysts, with 5 outperform and 10 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 27.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.41 a share, which would compare with $-0.01 in the same quarter last year. They have a high estimate of $0.46 and a low estimate of $0.37. Revenue for the period is expected to total nearly $587.71M from $424.12M the year-ago period.

For the full year, 27.00 Wall Street analysts forecast this company would deliver earnings of 1.77 per share, with a high estimate of $1.90 and a low estimate of $1.60. It had reported earnings per share of $1.20 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $2.38B versus 2.09B in the preceding year.

The analysts project the company to maintain annual growth of around 10.90% percent over the next five years as compared to an average growth rate of 8.20% percent expected for its competitors in the same industry.

Among the 25 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for ZION is $30.48 but some analysts are projecting the price to go as high as $36.00. If the optimistic analysts are correct, that represents a 28 percent upside potential from the recent closing price of $28.16. Some sell-side analysts, particularly the bearish ones, have called for $22.00 price targets on shares of Zions Bancorp (NASDAQ:ZION) .

In the last reported results, the company reported earnings of $-0.01 per share, while analysts were calling for share earnings of $0.38. It was an earnings surprise of -102.60%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Zions Bancorporation, a financial holding company, provides a range of banking and related services in Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. The company offers community banking services, such as small and medium-sized business and corporate banking; commercial and residential development, construction, and term lending; retail banking; treasury cash management and related products and services; and residential mortgage servicing and lending. It also provides trust and wealth management services; capital markets services, including municipal finance advisory and underwriting; and investment services. In addition, the company offers personal banking services to individuals, including home mortgages, bankcards, other installment loans, home equity lines of credit, checking accounts, savings accounts, certificates of deposit of various types and maturities, safe deposit facilities, direct deposits, and Internet and mobile banking services. Further, it provides online and traditional brokerage services; small business administration and secondary market agricultural real estate mortgage loans; and bond transfer, stock transfer, and escrow services for corporate customers. As of December 31, 2015, the company operated 450 domestic branches. Zions Bancorporation was founded in 1873 and is headquartered in Salt Lake City, Utah.

Analyst’s Keeping an Eye on Callon Petroleum Company (NYSE:CPE)

Analysts are weighing in on how Callon Petroleum Company (NYSE:CPE), might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.8. The stock is rated as buy by 14 analysts, with 6 outperform and 1 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 21.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.02 a share, which would compare with $0.04 in the same quarter last year. They have a high estimate of $0.06 and a low estimate of $-0.04. Revenue for the period is expected to total nearly $45.56M from $39.24M the year-ago period.

For the full year, 21.00 Wall Street analysts forecast this company would deliver earnings of 0.10 per share, with a high estimate of $0.23 and a low estimate of $-0.40. It had reported earnings per share of $0.14 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $190.36M versus 137.51M in the preceding year.

The analysts project the company to maintain annual growth of around 97.39% percent over the next five years as compared to an average growth rate of 8.52% percent expected for its competitors in the same industry.

Among the 20 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CPE is $13.91 but some analysts are projecting the price to go as high as $18.00. If the optimistic analysts are correct, that represents a 52 percent upside potential from the recent closing price of $11.87. Some sell-side analysts, particularly the bearish ones, have called for $10.00 price targets on shares of Callon Petroleum Company (NYSE:CPE).

In the last reported results, the company reported earnings of $0.04 per share, while analysts were calling for share earnings of $0.00. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Callon Petroleum Company, an independent oil and natural gas company, acquires, explores for, develops, and produces oil and natural gas properties in the Permian Basin in West Texas. As of December 31, 2015, the company estimated net proved reserves totaled 54.3 million barrel of oil equivalent. Callon Petroleum Company was founded in 1950 and is headquartered in Natchez, Mississippi.

Analyst’s Keeping an Eye on Intrexon Corp (NYSE:XON)

Analysts are weighing in on how Intrexon Corp (NYSE:XON), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.1. The stock is rated as buy by 3 analysts, with 2 outperform and 3 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 8.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.24 a share, which would compare with $-0.37 in the same quarter last year. They have a high estimate of $-0.12 and a low estimate of $-0.37. Revenue for the period is expected to total nearly $53.83M from $44.89M the year-ago period.

For the full year, 8.00 Wall Street analysts forecast this company would deliver earnings of -1.30 per share, with a high estimate of $-0.94 and a low estimate of $-1.68. It had reported earnings per share of $-0.76 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $207.44M versus 173.60M in the preceding year.

The analysts project the company to maintain annual growth of around -67.40% percent over the next five years as compared to an average growth rate of 25.76% percent expected for its competitors in the same industry.

Among the 8 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for XON is $45.50 but some analysts are projecting the price to go as high as $65.00. If the optimistic analysts are correct, that represents a 158 percent upside potential from the recent closing price of $25.20. Some sell-side analysts, particularly the bearish ones, have called for $29.00 price targets on shares of Intrexon Corp (NYSE:XON).

In the last reported results, the company reported earnings of $-0.37 per share, while analysts were calling for share earnings of $-0.04. It was an earnings surprise of -825.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; RheoSwitch inducible gene switch; Cell Systems Informatics; AttSite Recombinases; Protein Engineering; antibody discovery; LEAP processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor altering chemical or antioxidant additives; and commercial aquaculture products. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Analyst’s Keeping an Eye on Monsanto Company (NYSE:MON)

Analysts are weighing in on how Monsanto Company (NYSE:MON), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.5. The stock is rated as buy by 7 analysts, with 3 outperform and 8 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 17.00 analysts offering adjusted EPS forecast have a consensus estimate of $2.42 a share, which would compare with $2.39 in the same quarter last year. They have a high estimate of $2.73 and a low estimate of $2.16. Revenue for the period is expected to total nearly $4.50B from $4.58B the year-ago period.

For the full year, 19.00 Wall Street analysts forecast this company would deliver earnings of 4.63 per share, with a high estimate of $4.80 and a low estimate of $4.26. It had reported earnings per share of $5.73 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $13.69B versus 15.00B in the preceding year.

The analysts project the company to maintain annual growth of around 8.14% percent over the next five years as compared to an average growth rate of 14.87% percent expected for its competitors in the same industry.

Among the 15 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for MON is $104.80 but some analysts are projecting the price to go as high as $132.00. If the optimistic analysts are correct, that represents a 21 percent upside potential from the recent closing price of $109.15. Some sell-side analysts, particularly the bearish ones, have called for $80.00 price targets on shares of Monsanto Company (NYSE:MON).

In the last reported results, the company reported earnings of $2.39 per share, while analysts were calling for share earnings of $2.07. It was an earnings surprise of 15.50%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Monsanto Company, together with its subsidiaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces raw crop seeds, including corn, soybean, cotton, and canola seeds under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds, such as tomato, pepper, melon, cucumber, squash, beans, broccoli, onions, lettuce, and others under the Seminis and De Ruiter brands. It also develops biotechnology traits that assist farmers in controlling insects and weeds in corn, soybean, cotton, and canola crops under the SmartStax, YieldGard, YieldGard VT Triple, VT Triple PRO, and VT Double PRO brands; and Intacta RR2 PRO, and Bollgard and Bollgard II, as well as Roundup Ready and Roundup Ready 2 Yield, and Genuity brands. This segment also licenses a range of germplasm and trait technologies to large and small seed companies. The Agricultural Productivity segment manufactures and sells herbicides for agricultural, industrial, ornamental, turf, and residential lawn and garden applications for weed control, as well as for control of preemergent annual grass and small seeded broadleaf weeds in corn and other crops under the Roundup and Harness brands. The company markets its products through distributors, independent retailers and dealers, agricultural cooperatives, plant raisers, and agents, as well as directly to farmers. Monsanto Company has a collaborative agreement with Novozymes to discover, develop, and produce microbial solutions. The company was formerly known as Monsanto Ag Company and changed its name to Monsanto Company in March 2000. Monsanto Company was founded in 2000 and is headquartered in St. Louis, Missouri.

Analyst’s Ratings on CVS Health Corporation (NYSE:CVS)

Analysts are weighing in on how CVS Health Corp (NYSE:CVS), might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.8. The stock is rated as buy by 12 analysts, with 10 outperform and 4 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 24.00 analysts offering adjusted EPS forecast have a consensus estimate of $1.30 a share, which would compare with $1.22 in the same quarter last year. They have a high estimate of $1.32 and a low estimate of $1.28. Revenue for the period is expected to total nearly $44.30B from $37.17B the year-ago period.

For the full year, 25.00 Wall Street analysts forecast this company would deliver earnings of 5.83 per share, with a high estimate of $5.90 and a low estimate of $5.79. It had reported earnings per share of $5.16 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $181.34B versus 153.29B in the preceding year.

The analysts project the company to maintain annual growth of around 14.93% percent over the next five years as compared to an average growth rate of 12.01% percent expected for its competitors in the same industry.

Among the 20 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CVS is $113.30 but some analysts are projecting the price to go as high as $123.00. If the optimistic analysts are correct, that represents a 31 percent upside potential from the recent closing price of $94.02. Some sell-side analysts, particularly the bearish ones, have called for $99.00 price targets on shares of CVS Health Corp (NYSE:CVS).

In the last reported results, the company reported earnings of $1.22 per share, while analysts were calling for share earnings of $1.20. It was an earnings surprise of 1.70%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order and specialty pharmacy services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services. This segment serves employers, insurance companies, unions, government employee groups, health plans, managed Medicaid plans and plans offered on public and private exchanges, other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS Pharmacy, CVS Specialty, Accordant, SilverScript, NovoLogix, Coram, Navarro Health Services, and Advanced Care Scripts names. As of December 31, 2015, it operated 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies and 5 mail order dispensing pharmacies, and 83 branches for infusion and enteral services. The Retail/LTC segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, and greeting cards, as well as provides photo finishing services. It operates 9,655 retail stores in 49 states, the District of Columbia, Puerto Rico, and Brazil primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy, and Drogaria Onofre names; online retail pharmacy Websites; and 32 onsite pharmacy stores, long-term care pharmacy operations, and retail health care clinics. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1892 and is headquartered in Woonsocket, Rhode Island.